Please assess the completion status of the following clinical trial:

Trial Title: Antithrombotic Effects of Ticagrelor Versus Clopidogrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers between 18 and 65 years old.~* Body mass index (BMI) 18 - 30 kg/m2 inclusive.~* Healthy as assessed by a detailed medical history and physical examination.~* Laboratory est results within the normal range.~* Ability to provide signed informed consent.~Exclusion Criteria:~* History of clinically relevant disease, bleeding, acute infectious disease or signs of acute illness.~* Allergy or hypersensitivity to aspirin or thienopyridines, or atopy diagnosed by a physician.~* Use of medication within one month prior to study drug administration.~* History of drug abuse or alcohol consumption \>20 g/day.~* Inability to abstain from intensive muscular effort or sport competition.~* Loss of \>400 mL blood or blood donation within 3 months.~* Positive serology for hepatitis B (HBs Ag) or hepatitis C.~* Conditions associated with hemorrhagic risk.~* Positive pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ticagrelor + ASA + Bivalirudin (Type: EXPERIMENTAL): Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
- Clopidogrel + ASA + Bivalirudin (Type: ACTIVE_COMPARATOR): Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).